Enveric is developing new and improved medicines to treat physical and mental ailments stemming from cancer and other conditions. Our mission is to improve the characteristics of psychedelic- and cannabinoid-derived pharmaceuticals by unlocking their full potential to create treatment solutions for a variety of indications with serious unmet medical needs.
| Name | Enveric Biosciences |
|---|---|
| Symbol | ENVB |
| Website | https://www.enveric.com/ |
| https://twitter.com/Enveric_Bio |
Press
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., CEO and Director, has issued a Letter to Shareholders to provide an update on the Company’s development program and recent events. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER To Our Valued Shareholders, This is a very exciting time in the growth and evolution of Enveric. We have successfully completed a strategic reshaping of the company to focus…
Press
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders. The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application. The application titled, “N-Hetercycle Substituted Tryptamine Derivatives and Methods of Using,”…
Press
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025. Additionally, Enveric will attend Biotech Showcase 2025 from January 13-15, 2025. Both conferences are being held in San Francisco during “J.P. Morgan Week 2025.” During the events, members of Enveric’s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business…